Resource impact statement

Cancer Drugs Fund technology

NICE has recommended atezolizumab for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable.

Atezolizumab will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and Roche have a commercial access agreement that makes atezolizumab available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.

The resource impact of atezolizumab will be covered by the Cancer Drugs Fund budget. The data collection period is expected to end in December 2020, when the final analyses of the IMvigor 130 trial are available. The process for exiting the Cancer Drugs Fund will begin at this point and the review of the NICE guidance will start. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry.

It is estimated that up to 1,000 people per year with metastatic urothelial carcinoma are eligible for treatment with atezolizumab.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.

This page was last updated: 06 December 2017